Introduction
This Modern Slavery and Human Trafficking Statement is a response to Section 54(1), Part 6 of the Modern Slavery Act
2015 and relates to actions and activities for the financial year ending 30 June 2021.

BioSpectrum Ltd ('the Company', 'we', 'us' or 'our') is committed to preventing slavery and human trafficking violations in its
own operations, its supply chain, and its products. We have zero-tolerance towards slavery and require our supply chain to
comply with our values.

Organisational structure
BioSpectrum Ltd has business operations in the United Kingdom.

 

We operate in the medical equipment supply sector. The nature of our supply chains is as follows: We work with several key direct suppliers, who provide us with medical devices for supply to hospitals within the NHS and private.

 

For more information about the Company, please visit our website: www.bio-spectrum.co.uk.
 

Policies
We operate a number of internal policies to ensure that we are conducting business in an ethical and transparent
manner.

 

These include the following:

• Supplier code of conduct - We operate this policy to ensure our suppliers operate in full compliance with the
laws and regulations of the countries in which they operate, and to seek similar commitments across their own
supply chain.

• Whistleblowing policy - We operate this policy so that employees are able to raise concerns about how staff
are being treated or practices within our business or our supply chains without fear of reprisal.

• Procurement policy - We want to make sure that potential suppliers are committed to ensuring that slavery
and human trafficking is not taking place within their own supply chains. Our procurement policy and
supporting procedures set out controls and checks undertaken to help verify this.

 

We make sure our suppliers are aware of our policies and adhere to the same standards.
 

Due Diligence
As part of our efforts to monitor and reduce the risk of slavery and human trafficking occurring in our supply chains, we
have adopted the following due diligence procedures:

 

• Internal supplier audits.
• External supplier audits.

 

Our due diligence procedures aim to:

 

• Identify and action potential risks in our business and supply chains.
• Monitor potential risks in our business and supply chains.
• Reduce the risk of slavery and human trafficking occurring in our business and supply chains.
• Provide protection for whistle-blowers.
Risk and compliance
 

Risk and compliance
The Company has evaluated the nature and extent of its exposure to the risk of slavery and human trafficking occurring
in its UK supply chain through:

• Evaluating the slavery and human trafficking risks of each new supplier.
• Creating an annual risk profile for key suppliers.
• Reviewing on a regular basis all aspects of the supply chain based on supply chain mapping.

We consider that we operate in a high-risk environment because The business operates in this risk level because
we purchase medical devices from China, where there is a potentially greater exposure to modern slavery as
human rights protections are more limited; sector or industry risks (i.e. what parts of the business may be
vulnerable to modern slavery); and business or transaction risk (i.e. particular relationships or transactions may
be more susceptible to modern slavery).

We do not tolerate slavery and human trafficking in our supply chains. Where there is evidence of failure to comply with our
policies and procedures by any of our suppliers, we will seek to terminate our relationship with that supplier immediately.

Effectiveness
The Company uses Key Performance Indicators (KPIs) to measure its effectiveness and ensure that slavery and human
trafficking is not taking place in its business and supply chains. These KPIs are as follows:

• We will contact suppliers to enquire about their modern slavery practices every 6 months.
• We will train our staff about modern slavery issues and increase awareness within the Company.
• We will carry out a regular audit of suppliers - 100% of suppliers each year.
 

Training our staff
The Company requires its staff to complete training and ongoing refresher courses on slavery and human trafficking.
The Company's training covers:

• How to identify the signs of slavery and human trafficking.
• What initial steps should be taken if slavery or human trafficking is suspected.
• How to escalate potential slavery or human trafficking issues to the relevant parties within the Company.
• What external help is available.
• What steps the Company should take if suppliers in its supply chain do not implement anti-slavery policies in
high risk scenarios, including their removal from the Company's supply chain.

​

The statement was approved by the board of directors.

Date: 19/4/2022

​

BioSpectrum Net Zero Policy

As a Board of Directors, we are determined to confront climate change and minimize the impact our business has upon the environment. 

BioSpectrum is committed to achieving Net Zero by 2040 for scope 1 and 2 emissions and by 2045 for scope 3 emissions.

 

This commitment was made on 17/11/2023.

​

​

​

​

Adam McQuilkin

Managing Director

​

​